secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2026-05-18T11:15:03+00:00
Accession:  0000885725-26-000041
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific invests $1.5B for ~34% stake in MiRus, gains option to acquire TAVR system for $3B
--------------------------------------------------------------------------------

- Paid $1.5B cash for 33.75% non-voting equity in MiRus; exclusive call option to buy TAVR business for $3.0B upon clinical/regulatory milestones.
- SIEGEL TAVR valve uses proprietary rhenium alloy, nickel-free, balloon-expandable, delivered through 8 Fr sheath; still investigational.
- Option includes right to acquire mitral/tricuspid replacement assets; if option not exercised, equity stake forfeited or reduced ~75%.
- MiRus initiated STAR pivotal trial (up to 1,025 patients) evaluating SIEGEL valve; early feasibility study presented in 2025.
- Investment expected immaterial to 2026 adjusted EPS; collaboration aims to bring differentiated TAVR system to aortic stenosis market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000041/0000885725-26-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000041/bsx-20260518.htm
  HTML page:      https://secwatch.observer/filing/0000885725-26-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer